Nektar Therapeutics (NKTR) Change in Receivables (2010 - 2024)

Nektar Therapeutics' Change in Receivables history runs 15 years deep, the most recent figure standing at $2.2 million for Q4 2024.

• In Q4 2024, Change in Receivables rose 320.62% year-over-year to $2.2 million; the TTM figure through Sep 2025 stood at $2.2 million (up 1494.94% YoY), while the FY2024 annual figure was $3.0 million, up 163.76% from the prior year.
• Change in Receivables was $2.2 million for Q4 2024 at Nektar Therapeutics, up from $850000.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $7.7 million in Q1 2022 to a low of -$20.2 million in Q2 2022.
• Historically, Change in Receivables has averaged -$1.6 million across 5 years, with a median of -$642000.0 in 2021.
• The sharpest annual moves came in 2020 and 2022: Change in Receivables soared 1739.18% in 2020, then sank 6992.63% in 2022.
• A 5-year view of Change in Receivables shows it stood at -$8.0 million in 2020, then jumped by 68.87% to -$2.5 million in 2021, then tumbled by 121.86% to -$5.6 million in 2022, then soared by 82.0% to -$999000.0 in 2023, then jumped by 320.62% to $2.2 million in 2024.
• The last three Change in Receivables figures came in at $2.2 million (Q4 2024), $850000.0 (Q3 2024), and -$2.4 million (Q2 2024), per Business Quant data.